Breaking News Instant updates and real-time market news.

HALO

Halozyme

$17.04

-0.19 (-1.10%)

16:05
05/07/19
05/07
16:05
05/07/19
16:05

Halozyme reaffirms FY19 revenue view $205M-$215M, consensus $209.09M

Sees FY19 revenue from royalties of $72M-$74M, with the decrease primarily attributable to the ongoing impact from biosimilars in Europe and updated expectations for the US launched products; product sales related to API increased to reflect additional customer orders; operating expenses of $265M-$275M, or $225M-$235M excluding an expected increase in cost of goods sold; operating cash burn of $45M-$55M; debt repayment of approximately $90Mm the company expects to pay off the remainder of the royalty-backed debt by the end of the Q1 of FY20; and year-end cash, cash equivalents and marketable securities balance of $210M-$220M.

  • 07

    May

  • 22

    May

  • 23

    May

  • 31

    May

HALO Halozyme
$17.04

-0.19 (-1.10%)

11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.

TODAY'S FREE FLY STORIES

11:25
05/23/19
05/23
11:25
05/23/19
11:25
General news
Treasury announced $113 B in shorter coupons for auction »

Treasury announced $113 B…

11:25
05/23/19
05/23
11:25
05/23/19
11:25
Conference/Events
Stephens medical devices analyst to hold a group luncheon »

Medical Devices &…

ECA

Encana

$6.05

-0.435 (-6.71%)

11:20
05/23/19
05/23
11:20
05/23/19
11:20
Options
Notable call buy in Encana as shares dip »

Notable call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTOO

T2 Biosystems

$1.88

-0.685 (-26.76%)

11:19
05/23/19
05/23
11:19
05/23/19
11:19
Hot Stocks
T2 Biosystems highlights clinical data at ECCMID, MAD-ID meetings »

T2 Biosystems highlighted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
05/23/19
05/23
11:17
05/23/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
05/23/19
05/23
11:16
05/23/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
05/23/19
05/23
11:15
05/23/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
05/23/19
05/23
11:15
05/23/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

MICT

Micronet Enertec

$0.99

(0.00%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Hot Stocks
Micronet Enertec receives two orders totaling $1.3M for SmartHub platform »

MICT announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$19.64

-0.31 (-1.55%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Hot Stocks
EQT Corporation files definitive proxy, mails letter to shareholders »

EQT Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTHT

Huazhu Group

$32.60

-1.81 (-5.26%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Downgrade
Huazhu Group rating change  »

Huazhu Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

USO

United States Oil Fund

$12.09

-0.66 (-5.18%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Options
Customer rolls US Oil ETF puts for 233% gain as oil sells off »

Customer rolls US Oil ETF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$104.01

-4.86 (-4.46%)

11:09
05/23/19
05/23
11:09
05/23/19
11:09
Syndicate
Rattler Midstream opens at $18.06, IPO priced at $17.50 per share »

Rattler Midstream (RTLR)…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$104.01

-4.86 (-4.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

FCX

Freeport McMoRan

$9.94

-0.11 (-1.09%)

11:05
05/23/19
05/23
11:05
05/23/19
11:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

IBM

IBM

$132.49

-3.53 (-2.60%)

11:04
05/23/19
05/23
11:04
05/23/19
11:04
Hot Stocks
ProcessMap, IBM announce joint initiative to develop IoT solutions »

ProcessMAP and IBM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

11:04
05/23/19
05/23
11:04
05/23/19
11:04
General news
Kansas City Fed Manufacturing Index Level data reported »

May Kansas City Fed…

LB

L Brands

$24.88

0.59 (2.43%)

10:59
05/23/19
05/23
10:59
05/23/19
10:59
On The Fly
Analysts remain cautious on L Brands despite stronger quarter »

Shares of L Brands (LB)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 22

    Aug

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

10:57
05/23/19
05/23
10:57
05/23/19
10:57
Syndicate
Breaking Syndicate news story on IDEAYA Biosciences »

IDEAYA Biosciences opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CNX

CNX Resources

$7.56

-0.26 (-3.32%)

10:50
05/23/19
05/23
10:50
05/23/19
10:50
Options
Size put option block in CNX after calls bought yesterday »

Size put option block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

10:50
05/23/19
05/23
10:50
05/23/19
10:50
General news
Treasury Action: yields have extended lower as Wall Street sinks »

Treasury Action: yields…

AZZ

AZZ Inc.

$43.62

(0.00%)

10:46
05/23/19
05/23
10:46
05/23/19
10:46
Hot Stocks
AZZ Inc. discloses change in independent registered public accounting firm »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$39.97

-0.22 (-0.55%)

10:45
05/23/19
05/23
10:45
05/23/19
10:45
Hot Stocks
GSK to change sales representative incentive program »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
he April U.S. new home sales report beat estimates »

The April U.S. new home…

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
Kansas City Fed Manufacturing Index Level to be reported at 11:00 »

May Kansas City Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.